Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IOngoingNov 29, 2023LEADER brand Lubricant Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0133-2024Class IOngoingNov 29, 2023LEADER brand Dry Eye ReliefNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0132-2024Class IOngoingNov 29, 2023LEADER brand Eye Irritation ReliefNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.Cardinal Health Inc. · D-0131-2024Class IOngoingNov 29, 2023ELCYS (cysteine hydrochloride injection)Presence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0118-2024Class IOngoingNov 29, 2023Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mLPresence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0117-2024Class IOngoingNov 29, 20238.4% Sodium Bicarbonate InjectionPresence of Particulate Matter: SiliconeExela Pharma Sciences LLC · D-0116-2024Class IITerminatedNov 29, 2023TiglutikFailed Viscosity Specifications: Out-of-specification test results for viscosityItf Pharma Inc · D-0115-2024Class IIITerminatedNov 29, 2023Lisinopril Tablets USP 20 mgPresence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lotsNCS Healthcare of Kentucky Inc · D-0114-2024Class IIITerminatedNov 29, 2023Buspirone Hydrochloride Tabs USP 10 mgPresence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lotsNCS Healthcare of Kentucky Inc · D-0113-2024Class IIITerminatedNov 29, 2023Esomeprazole Magnesium Delayed-Release CapsulesFailed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in...Glenmark Pharmaceuticals Inc., USA · D-0112-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC 70-VACGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0111-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC70-LVCGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0110-2024Class IITerminatedNov 29, 2023Integrity Biochem HSC 70-LMCGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.Integrity Bio-Chemicals LLC · D-0109-2024Class ITerminatedNov 29, 2023Lubricating Tears Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0108-2024Class ITerminatedNov 29, 2023Polyvinyl Alcohol 1.4% Lubricating Eye DropsNon-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0107-2024Class IITerminatedNov 22, 2023Oxygen, Compressed USPcGMP DeviationsFamily Medical Supply Inc · D-0106-2024Class IIOngoingNov 22, 2023Equate Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0105-2024Class IIOngoingNov 22, 2023DOP Instant Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0104-2024Class IIOngoingNov 22, 2023DOP Instant Hand SanitizerSub Potent and Super Potent Product: During an impact assessment of the DOP Hand Sanitizer product, it was identified that several lots distributed did not comply with...Omega & Delta Co., Inc. · D-0103-2024Class ITerminatedNov 15, 20232% Lidocaine HCl InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0102-2024Class ITerminatedNov 15, 20231% Lidocaine HCl InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0101-2024Class ITerminatedNov 15, 20234.2% Sodium Bicarbonate InjectionPresence of Particulate Matter: identified as glass.Pfizer Inc. · D-0100-2024Class IIITerminatedNov 15, 2023V-FORCE HomeopathicIncorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product...Grato Holdings, Inc. · D-0099-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0098-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0097-2024Class IICompletedNov 15, 2023Oxybutynin Chloride Extended-Release Tablet USPFailed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.Zydus Pharmaceuticals (USA) Inc · D-0096-2024Class IIOngoingNov 15, 2023Deferasirox Tablets for Oral SuspensionFailed Dissolution SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0095-2024Class IIIOngoingNov 15, 2023Oxaydo (oxycodone HClSub-potent Drug: Lower potency than labeled.Zyla Life Sciences US Inc. · D-0094-2024Class IIITerminatedNov 15, 2023Mycophenolate Mofetil for Oral SuspensionDefective Container: The adaptor does not fit into the neck of the bottle after reconstitution with water.VistaPharm LLC · D-0093-2024Class IIOngoingNov 15, 2023Ranolazine Extended-Release Tablets 500mgFailed Dissolution Specifications: Out of specification for dissolution.Glenmark Pharmaceuticals Inc., USA · D-0092-2024Class IITerminatedNov 15, 2023Clinical TREAT Antifungal PowderCGMP deviations: the product was shipped from the Manufacturer to a Medline warehouse and released to stock while it was still under investigation for low assay results...MEDLINE INDUSTRIES, LP - Northfield · D-0091-2024Class IITerminatedNov 15, 2023Extended Phenytoin Sodium CapsulesFailed Dissolution SpecificationsAmneal Pharmaceuticals of New York, LLC · D-0090-2024Class IIITerminatedNov 15, 2023Hydrocortisone 1% and Acetic Acid 2% Otic Solution USPFailed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the...Taro Pharmaceuticals Inc. · D-0089-2024Class IIIOngoingNov 15, 2023SynthroidLabeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg...AbbVie Inc. · D-0088-2024Class IITerminatedNov 15, 2023Buprenorphine HClCrystallization; identified as Buprenorphine free basePAR Sterile Products LLC · D-0087-2024Class IITerminatedNov 15, 2023Montelukast Sodium TabletsPresence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.Dr. Reddy's Laboratories, Inc. · D-0086-2024Class IIITerminatedNov 8, 2023Bisoprolol Fumarate and Hydrochlorothiazide TabletsFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0085-2024Class IITerminatedNov 8, 2023Liothyronine Sodium TabletsFailed Impurities/Degradation Specifications.Sun Pharmaceutical Industries Inc · D-0084-2024Class IITerminatedNov 8, 2023Liothyronine Sodium TabletsFailed Impurities/Degradation Specifications.Sun Pharmaceutical Industries Inc · D-0083-2024Class IITerminatedNov 8, 2023Strong Iodine Solution U.S.PCGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.Safecor Health, LLC · D-0082-2024